Skip to content

Effect of Metformin on reducing platelet dysfunction in gestational diabetes mellitus: A randomized controlled trial

Effect of Metformin on reducing platelet dysfunction in gestational diabetes mellitus: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200517003
Enrollment
72
Registered
2020-05-17
Start date
2020-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant women with GDM typically have different levels of insulin resistance and chronic low&#45

Interventions

Each woman in the intervention group will be given Metformin (500 mg) 1 tablet oral once a day since 30 to 32 weeks’ gestation throughout the entire study period.,For the control group&#44
each woman will be given placebo 1 tablet oral once a day. The placebo was produced from Faculty of Pharmacy&#44
Chiang Mai University
Experimental Drug,Placebo Comparator Drug
Metformin,Placebo

Sponsors

None listed

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Women undergoing antenatal care and vaginal delivery at Maharaj Nakorn Chiang Mai Hospital (Faculty of Medicine, Chiang Mai University) 2. Age 20-45 years 3. The patients with gestational diabetes mellitus (GDM) diagnosed based on the National Diabetes Data Group (NDDG) criteria since 20 weeks’ gestation. 4. All women with GDM had normal medical histories before pregnancy

Exclusion criteria

Exclusion criteria: 1. Patients with GDM whose blood glucose was poor controlled which need insulin therapy 2. Women with systemic diseases such as hypertension, heart disease, renal disease, connective tissue disease, hepatic disease 3. Women with twin pregnancy, major structural fetal anomaly, pregnancy-induced hypertension, and preterm labor in this pregnancy 4. Poor obstetric history requiring medication during gestation eg. recurrent pregnancy loss, previous occurrence of pre-eclampsia, preterm labor, intrauterine growth restriction

Design outcomes

Primary

MeasureTime frame
Mean platelet volume (MPV) In third trimester of pregnancy and intrapartum A peripheral venous blood sample, to measure complete blood count (CBC) parameters ,The blood clotting time of pregnant woman Intrapartum The whole blood clotting test,The estimate blood loss after vaginal delivery During vaginal delivery Postpartum blood loss collected via a plastic scale collecting bag

Secondary

MeasureTime frame
The clotting time of cord blood During vaginal delivery The whole blood clotting test,Post-vaginal delivery complications Postpartum Post-vaginal delivery complications

Countries

Thailand

Contacts

Public ContactPanisa Hantrakun

Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University

medpanisa089@gmail.com0839625522

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026